Company Overview

Hims & Hers Health, Inc. is an American telehealth company established in 2017 that has transformed the healthcare landscape through its innovative direct-to-consumer model. The company was founded in 2017 and is headquartered in San Francisco, CA. Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology, and primary care.

Business Model & Operations

Hims & Hers operates with a direct-to-consumer model. Consumers consult licensed healthcare professionals and access treatments and products through the company's platform. Customers pay for a consultation with a doctor to prescribe medication, along with the price of the drug itself.

The company's comprehensive platform includes:

- Access to a provider network.

- A clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities.

- A range of curated prescription and non-prescription health and wellness products and services available for purchase on its websites and mobile application directly by customers.

Service Offerings

The company provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care.

Key Specialties:

- General Wellness: Melatonin and biotin products.

- Skincare: Moisturizers, creams, sunscreen, serum, face oil, and face wash.

- Sexual Health: Comprehensive wellness solutions.

- Hair Care: Shampoos, conditioners, scalp scrubs, and topical treatments including minoxidil.

- Mental Health Services: Professional consultation and ongoing support.

---

Financial Performance and Market Position

The company has demonstrated significant growth in revenue and subscriber base, positioning itself as a leader in the direct-to-consumer telehealth market. While specific market cap and promoter holding data are not provided in the source, its operational metrics indicate strong expansion.

Recent Financial Highlights

Full Year 2024 Results:

- Revenue of $1.5 billion, up 69% year-over-year in 2024.

- Net income of $126 million; Adjusted EBITDA of $177 million in 2024.

- Subscribers grew to 2.2 million, up 45% year-over-year in 2024.

Q2 2025 Performance:

- Revenue of $544.8 million, up 73% year-over-year in Q2 2025.

- Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025.

- Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025.

Q1 2025 Performance:

- Revenue of $586.0 million, up 111% year-over-year in Q1 2025.

- Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025.

Key Financial Metrics

- EBITDA: $166.05 million USD.

- Current EBITDA Margin: 5.76%.

- Dividends: HIMS does not pay dividends to its shareholders.

- Employees: As of Sep 23, 2025, the company has 1.64K employees.

---

Growth Strategy and Market Position

2025 Outlook

The company provides guidance for Q1 and full year 2025. Full year 2025 revenue is projected to be in the range of $2.3 billion to $2.4 billion, demonstrating strong confidence in its continued growth trajectory.

Strategic Advantages

- Diversification: Expansion into new health categories.

- Innovation: Integration of advanced technology within its platform.

- International Expansion: Growth opportunities in global markets.

These strategies are expected to drive sustained growth, operational efficiency, and increased global market share. Strong user adoption, enhanced personalized offerings, and industry trends toward telehealth position the company for higher recurring revenue and long-term earnings stability.

---

Market Reach and Operations

The company operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. This global presence positions Hims & Hers to capitalize on the expanding telehealth market worldwide.

---

Recent Developments and Challenges

The company has faced some regulatory scrutiny. Its shares experienced a significant drop after a collaboration with Novo Nordisk reportedly fell apart. The drugmaker stated that Hims & Hers "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization.

---

Investment Considerations

Hims & Hers Health, Inc. is covered by 21 analysts, with 14 providing revenue or earnings estimates. The company continues to demonstrate strong operational performance with consistent subscriber growth and expanding revenue streams.

The telehealth industry is poised for long-term growth as consumer preferences shift toward convenient and accessible healthcare solutions. Hims & Hers' established platform, growing subscriber base, and diversified service offerings make it a significant player in the evolving digital healthcare landscape.